In a 3-week study, the administration of up-titrated doses of the subcutaneous human GLP-1 analog liraglutide elicited significant increases of natriuresis independent of concomitant changes in blood pressure or circulating levels of natriuretic peptides in overweight or obese subjects with T2DM and hypertension [38]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.